四价登革疫苗基础-加强免疫后登革病毒1型人体攻击试验的有效性和免疫原性:一项开放标签1期试验
在美国马里兰大学开展开放标签1期试验,比较曾接种四价登革纯化灭活疫苗基础免疫加减毒活疫苗加强的受试者与未接种黄病毒初治者,经登革病毒1型攻击后,疫苗组未获保护,且出现炎症增加的临床、免疫学和转录组学证据,可能与预先存在的感染增强抗体有关。
要点
- 疫苗组6例中5例(83%)、对照组4例全部(100%)检出登革病毒1型RNA。
- 疫苗组RNA血症平均出现于第5天(SD 1.0),对照组第8天(SD 1.5),差异有统计学意义(p=0.007)。
- 严重不良事件仅见于疫苗组:发热≥38.9°C 3例(50%)、头痛1例(17%)、短暂4级天冬氨酸转氨酶升高1例(17%)。
核心结论
- 曾接受四价登革纯化灭活疫苗基础免疫和减毒活疫苗加强的受试者对登革病毒1型感染无保护。
- 疫苗组还显示炎症增加的临床、免疫学和转录组学证据,可能由预先存在的感染增强抗体介导。
研究设计与样本
- 在美国马里兰大学(巴尔的摩)开展开放标签1期试验。
- 受试者为18-50岁健康人,分疫苗组(既往四价登革纯化灭活疫苗基础免疫加减毒活疫苗加强)和对照组(未接种黄病毒初治者)。
- 疫苗组中攻击前登革病毒1型中和抗体滴度可检出者与对照组黄病毒初治者于加强接种后27-65个月经三角肌接种登革病毒1型45AZ5株。
- 攻击后第4-16天每日实时定量PCR检测登革病毒1型RNA,并记录局部和全身不良事件。
- 主要结局为安全性(局部和全身不良事件)和疫苗有效性(登革病毒1型RNA血症)。
主要发现
- 2021年1月入组10例,疫苗组6例(60%),对照组4例(40%)。
- 每日定量PCR检出登革病毒1型RNA:10例中9例(90%),疫苗组6例中5例(83%),对照组4例全部(100%)。
- RNA血症平均出现时间:疫苗组第5天(SD 1.0) vs 对照组第8天(SD 1.5),95%CI 1.1-4.9,p=0.007。
- RNA血症持续时间:疫苗组8.2天 vs 对照组10.5天,95%CI -0.08至4.68,p=0.056,疫苗组有缩短趋势。
- 轻至中度症状9/10例(90%)、白细胞减少8/9例(89%)、转氨酶升高7/9例(78%)常见。
局限性
- 原文指出本研究为小队列。
- 原文指出人体攻击模型用于研究登革发病机制及下游疫苗开发的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue human infection models (DHIMs) are important tools to down-select dengue vaccine candidates and establish tetravalent efficacy before advanced clinical field trials. We aimed to provide data for the safety and immunogenicity of DHIM and evaluate dengue vaccine efficacy. METHODS: We performed an open-label, phase 1 trial at the University of Maryland (Baltimore, MD, USA). Eligible participants were healthy individuals aged 18-50 years who either previously received a tetravalent dengue purified inactivated vaccine prime followed by a live-attenuated vaccine boost (ie, the vaccinee group), or were unvaccinated flavivirus-naive participants (ie, the control group). Participants in the vaccinee group with detectable pre-challenge dengue virus-1 neutralising antibody titres and flavivirus-naive participants in the control group were inoculated with dengue virus-1 strain 45AZ5 in the deltoid region, 27-65 months following booster dosing. These participants were followed-up from days 4-16 following dengue virus-1 live virus human challenge, with daily real-time quantitative PCR specific to dengue virus-1 RNA detection, and dengue virus-1 solicited local and systemic adverse events were recorded. The primary outcomes were safety (ie, solicited local and systemic adverse events) and vaccine efficacy (ie, dengue virus-1 RNAaemia) following dengue challenge. This study is registered with ClinicalTrials.gov, number NCT04786457. FINDINGS: In January 2021, ten eligible participants were enrolled; of whom, six (60%) were in the vaccinee group and four (40%) were in the control group. Daily quantitative PCR detected dengue virus-1 RNA in nine (90%) of ten participants (five [83%] of six in the vaccinee group and all four [100%] in the control group). The mean onset of RNAaemia occurred on day 5 (SD 1·0) in the vaccinee group versus day 8 (1·5) in the control group (95% CI 1·1-4·9; p=0·007), with a trend towards reduced RNAaemia duration in the vaccinee group compared with the control group (8·2 days vs 10·5 days; 95% CI -0·08 to 4·68; p=0·056). Mild-to-moderate symptoms (nine [90%] of ten), leukopenia (eight [89%] of nine), and elevated aminotransferases (seven [78%] of nine) were commonly observed. Severe adverse events were detected only in the vaccinee group (fever ≥38·9°C in three [50%] of six, headache in one [17%], and transient grade 4 aspartate aminotransferase elevation in one [17%]). No deaths were reported. INTERPRETATION: Participants who had tetravalent dengue purified inactivated vaccine prime and live-attenuated vaccine boost were unprotected against dengue virus-1 infection and further showed increased clinical, immunological, and transcriptomic evidence for inflammation potentially mediated by pre-existing infection-enhancing antibodies. This study highlights the impact of small cohort, human challenge models studying dengue pathogenesis and downstream vaccine development. FUNDING: Military Infectious Disease Research Program and Medical Technology Enterprise Consortium and Advanced Technology International.
引用
- Lyke KE, Chua JV, Koren M, et al. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial. Lancet Infect Dis. 2024. PMID: 38679035. doi:10.1016/S1473-3099(24)00100-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。